Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck CEO To Street: Watch For Short-term Adaptability, Long-Term Innovation

This article was originally published in The Pink Sheet Daily

Executive Summary

Newly named chairman, Merck’s CEO Ken Frazier, cites several – smallish – launches, flexibility, especially in the face of setbacks, and business development, and ongoing focus on innovation as priorities in 2012 that will lead to long-term sustainability.

You may also be interested in...



A Changing Of The Guard At Merck R&D As Perlmutter Succeeds Kim

Amid growing concern over the quality of Merck’s late-stage pipeline, CEO Frazier made a decisive move to change the R&D leadership; Former Amgen R&D head Perlmutter will succeed Merck Research Laboratories President Kim in April.

A Changing Of The Guard At Merck R&D As Perlmutter Succeeds Kim

Amid growing concern over the quality of Merck’s late-stage pipeline, CEO Frazier made a decisive move to change the R&D leadership. Former Amgen R&D head Perlmutter will succeed Merck Research Laboratories President Kim in April.

Europe’s Newest Biotech – Valneva – Formed As Intercell And Vivalis Marry

One of the few remaining independent biotech vaccine developers in Europe, Austria's Intercell, is to join forces with France's Vivalis in a proposed merger valued at $174 million to create a pipeline spanning from antibodies to vaccines.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073224

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel